Food and Drug Administration

Arthritis Advisory Committee

March 4, 2003


Introduction - Safety & Efficacy Update on Approved TNF-Blocking Agents, Dr. Jeffrey Siegel, MD, FDA (HTM) (PPT)

Update on the Safety of TNF Blockers, Dr. Li-ching Liang, MD, FDA (HTM) (PPT)

TNF Blocker Safety: Lymphoma and Liver Failure, Dr. Tim Cote, MD, FDA (HTM) (PPT)

Anti-TNF-a Strategies in CHF: Data from Randomized, Controlled Clinical Trials, Dr. Ellis Unger, MD, FDA (HTM) (PPT)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Safety Update on Humira™ Adalimumab for Rheumatoid Arthritis, Abbott Lab. (PDF)

Etanercept (Enbrel®) Safety Review, Amgen (HTM) (PPT)

Remicade® (Infliximab), Centocor (HTM) (PPT)

Adalimumab: Lymphomas, Dr. Jeffrey Siegel, MD, FDA (HTM) (PPT)